Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2025-12-29 @ 6:48 PM
Study NCT ID:
NCT00878228
Status:
COMPLETED
Last Update Posted:
2013-01-31
First Post:
2009-04-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy
Sponsor:
Hospital for Special Surgery, New York
Organization:
Study Overview
Official Title:
Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PDNV
Brief Summary:
The study is a randomized placebo controlled trial to determine whether repeated postoperative prophylactic ondansetron ("Zofran") administration will prevent postoperative and/or postdischarge nausea and vomiting in patients undergoing ambulatory hip arthroscopy. Ondansetron will be administered in the intra- and post-operative period. These individuals will be followed on postoperative days 1, 2, and 3. It is hypothesized that the incidence of postdischarge nausea and vomiting (PDNV) will be significantly decreased by postoperative prophylactic administration of multiple doses of ondansetron (Zofran).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: